Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc. (PLRX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
plrx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Pliant Therapeutics, Inc. (PLRX) measures how much investors pay for each dollar of the company's trailing earnings. PLRX's current PE ratio of N/A is calculated by dividing its stock price of $1.15 by its TTM earnings per share of -$1.83.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2017 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Pliant Therapeutics, Inc.You PLRX | $71M | N/A | — | -$1.83 |
 Adverum Biotechnologies, Inc. ADVM | $96M | N/A | — | -$6.62 |
 Artiva Biotherapeutics, Inc. ARTV | $168M | N/A | — | -$3.43 |
 Clene Inc. CLNN | $55M | N/A | — | -$2.65 |
 Coya Therapeutics, Inc. COYA | $83M | N/A | — | -$1.27 |
 Fractyl Health, Inc. Common Stock GUTS | $48M | N/A | — | -$1.86 |
 MacroGenics, Inc. MGNX | $247M | N/A | — | -$1.18 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-2.43 | — | |
2024-12-31 FY2024 | — | $-3.47 | — | |
2023-12-31 FY2023 | — | $-2.75 | — | |
2022-12-31 FY2022 | — | $-2.94 | — | |
2021-12-31 FY2021 | — | $-2.71 | — | |
2020-12-31 FY2020 | — | $-1.17 | — | |
2019-12-31 FY2019 | — | $-0.02 | — | |
2018-12-31 FY2018 | — | $-1.83 | — | |
2017-12-31 FY2017 | — | $-25.67 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Pliant Therapeutics, Inc. (PLRX) measures how much investors pay for each dollar of the company's trailing earnings. PLRX's current PE ratio of N/A is calculated by dividing its stock price of $1.15 by its TTM earnings per share of -$1.83.
Frequently asked questions
PLRX pe ratio · 6 questionsPLRX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.15 and TTM EPS of -$1.83. Data sourced from Financial Modeling Prep via PLRX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Pliant Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09